


Signals Magazine

Online Magazine Of Biotechnology Industry Analysis

www.SignalsMag.com


Financial Snapshot For February 2003: Waiting For War



The ever-present threat of war with Iraq has kept the capital markets in a state of extreme uncertainty for months now. It seems that Wall Street is holding its breath: Not surprisingly, there was little change in the overall market indices in February.

During the month, the Nasdaq Composite Index rose by a mere 1% and the Nasdaq Biotech Index dropped by 1%. The relatively flat performance was also evident in January. In fact, the Comp remains unchanged since the beginning of the year.

The Biotech Index, on the other hand, shed 4% between December 31, 2002 and February 28, 2003.



Over the last 12 months, the Nasdaq Biotech Index – which is comprised of the 72 largest and most actively traded biotech stocks – dropped by 36%, underperforming the Nasdaq Composite Index, which lost 23% between February 28, 2002 and February 28, 2003.

Many biotech stocks, however, have suffered more than a 36% drop over the last year. On February 28, 2003, the average 12-month change in price for the 226 stocks tracked by Recombinant Capital and *Signals* was minus 44% and the median change

was minus 52%.

On a positive note, the biotech stocks are still in better shape than they were in mid-July: Between July 10, 2002 and February 28, 2003, the Biotech Stock Index rose by 19% (while the Comp remained flat).

That's encouraging – but the stocks have a long way to go if they are ever to reach their former heights. Indeed, they may never soar to those levels again. Today marks the 3-year anniversary of the peak of the genomics bubble: On March 6, 2000, the Nasdaq Biotech Index stood at 1,596.53. On March 5, 2003, it closed at 476.06 – a wrenching decline of 70%. Interestingly, the Nasdaq Composite Index fared worse, plummeting by 73% between March 6, 2000 and March 5, 2003.

February 2003 Stock Report

The February 2003 Stock Report, published by Recombinant Capital and *Signals*, is the 33rd in a series. It includes detailed financial data on 226 publicly traded biotechnology stocks, based on their closing prices on February 28, 2003.

COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
GENOME THERAPEUTICS CORP	\$1.73	28%	-66%	\$ 40	\$54	-\$14	\$16	176	-\$0.1	-\$40.3	1.3	0.9
HUMAN GENOME SCIENCES	\$6.79	26%	-67%	\$874	\$1,352	-\$478	\$503	1010	-\$0.5	-\$300.3	4.5	0.5
INCYTE GENOMICS	\$3.38	26%	-69%	\$230	\$453	-\$223	\$172	585	-\$0.4	-\$153.6	2.9	0.3
MILLENNIUM PHARMACEUTICALS	\$7.16	28%	-62%	\$2,055	\$1,822	\$233	\$83	1900	\$0.1	na	na	0.5
MYRIAD GENETICS	\$9.78	26%	-70%	\$264	\$59	\$206	\$0	491	\$0.4	-\$21.3	2.8	1.3
1st Generation Genomics Average	.	27%	-67%	\$693	\$748	-\$55	\$155	.	-\$0.1	-\$128.9	2.9	0.7
1st Generation Genomics Median	.	27%	-67%	\$247	\$256	-\$6	\$50	.	\$0.0	-\$40.3	2.8	0.7
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
ACLARA BIOSCIENCES	\$2.00	52%	-44%	\$ 72	\$119	-\$47	\$1	170	-\$0.3	-\$44.8	2.7	0.3
AFFYMETRIX	\$26.39	85%	7%	\$1,541	\$353	\$1,188	\$370	905	\$1.3	na	na	4.4
CALIPER TECHNOLOGIES	\$3.26	23%	-70%	\$80	\$128	-\$48	\$0	132	-\$0.4	-\$37.5	3.4	0.3
CELERA GENOMICS GROUP	\$8.25	35%	-59%	\$590	\$880	-\$290	\$0	na	na	na	na	na
CEPHEID	\$3.98	60%	49%	\$123	\$21	\$102	\$2	143	\$0.7	-\$23.0	0.9	1.5
CIPHERGEN BIOSYSTEMS	\$5.00	69%	-13%	\$136	\$46	\$91	\$0	229	\$0.4	-\$31.6	1.4	0.8
COMBIMATRIX	\$2.05	41%	na	\$ 39	na	na	na	na	na	na	na	na
ILLUMINA	\$2.41	25%	-65%	\$ 78	\$ 0	\$78	\$0	179	\$0.4	-\$30.4	0.0	na
SEQUENOM	\$1.68	22%	-70%	\$ 66	\$106	-\$40	\$6	272	-\$0.1	-\$68.0	1.6	0.1
TRANSGENOMIC	\$1.93	21%	-76%	\$ 45	\$18	\$27	\$0	na	na	-\$18.9	1.0	0.4
Genomic Supply Average	.	43%	-38%	\$277	\$186	\$118	\$42	.	\$0.3	-\$36.3	1.6	1.1

PHARMACEUTICAL CO	\$1.59	64%	22%	\$ 56	\$ 7	\$48	\$0	12	\$4.0	-\$5.9	1.3	1.0
KERYX BIOPHARMACEUTICALS	\$1.55	26%	-67%	\$31	\$27	\$4	\$0	63	\$0.1	-\$12.1	2.2	0.4
LA JOLLA PHARMACEUTICAL CO	\$1.30	15%	-79%	\$ 55	\$65	-\$10	\$0	118	-\$0.1	-\$42.7	1.5	0.3
PROTEIN DESIGN LABS	\$7.65	37%	-52%	\$681	\$624	\$58	\$159	363	\$0.2	-\$32.0	19.5	1.1
TANOX	\$8.84	55%	-36%	\$392	\$235	\$157	\$5	114	\$1.4	-\$30.6	7.7	1.3
Autoimmune Average	.	52%	-33%	\$292	\$114	\$178	\$22	.	\$1.3	-\$36.7	4.5	0.9
Autoimmune Median	.	57%	-34%	\$ 56	\$28	\$15	\$0	.	\$1.2	-\$12.1	2.0	1.0
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
ALLOS THERAPEUTICS	\$4.40	44%	-27%	\$113	\$60	\$53	\$0	61	\$0.9	-\$21.2	2.8	0.7
ANTIGENICS	\$8.13	54%	-38%	\$269	\$70	\$198	\$0	208	\$1.0	-\$54.2	1.3	0.9
APHTON CORP	\$2.50	21%	-78%	\$ 57	\$ 9	\$48	\$0	50	\$1.0	-\$43.7	0.2	0.5
AVAX TECHNOLOGIES	\$0.13	19%	-75%	\$ 2	\$ 6	-\$4	\$0	43	-\$0.1	-\$10.4	0.6	0.0
AVI BIOPHARMA	\$3.16	28%	-66%	\$ 84	\$22	\$61	\$0	85	\$0.7	-\$28.2	0.8	0.6
BIOMIRA	\$1.09	26%	-71%	\$ 58	\$83	-\$25	\$0	179	-\$0.1	-\$17.6	4.7	0.6
BOSTON LIFE SCIENCES	\$0.93	32%	-62%	\$21	\$0	\$21	\$0	na	na	na	na	na
BRITISH BIOTECH PLC	\$2.19	24%	-73%	\$37	\$173	-\$136	\$3	145	-\$0.9	-\$36.2	4.8	0.1
CELGENE CORP	\$21.90	79%	-16%	\$1,724	\$289	\$1,435	\$0	383	\$3.7	-\$4.1	69.7	3.2
CELL PATHWAYS	\$0.81	14%	-82%	\$ 32	\$17	\$15	\$0	77	\$0.2	-\$18.9	0.9	0.2
CELL THERAPEUTICS	\$7.02	26%	-68%	\$229	\$169	\$60	\$0	238	\$0.3	-\$121.6	1.4	0.6
CORIXA CORP	\$5.99	53%	-39%	\$301	\$47	\$254	\$23	496	\$0.5	-\$66.3	0.7	0.2
CYTOGEN CORP	\$2.87	11%	-87%	\$25	\$16	\$9	\$3	74	\$0.1	-\$15.9	1.0	0.1
DENDREON	\$4.10	57%	26%	\$108	\$55	\$53	\$0	72	\$0.7	-\$20.8	2.6	0.7
DOR BIOPHARMA	\$1.05	61%	-19%	\$ 23	\$ 4	\$19	\$0	22	\$0.8	-\$2.5	1.6	0.3
DUSA PHARMACEUTICALS	\$1.52	29%	-61%	\$ 21	\$56	-\$35	\$2	55	-\$0.6	na	na	0.2
ENTREMED	\$1.04	11%	-86%	\$ 23	\$ 5	\$18	\$3	112	\$0.2	-\$47.0	0.1	0.1
EXEGENICS	\$0.59	29%	-65%	\$ 10	\$20	-\$10	\$0	29	-\$0.4	-\$10.7	1.9	0.1
GENAERA	\$0.32	9%	-89%	\$ 11	\$12	-\$1	\$0	57	\$0.0	-\$11.9	1.0	0.1
GENTA	\$6.55	35%	-49%	\$479	\$127	\$352	\$10	60	\$5.9	-\$60.4	2.1	1.5
GERON CORP	\$1.69	19%	-77%	\$ 42	\$47	-\$6	\$16	142	\$0.0	-\$28.8	1.6	0.2
ILEX ONCOLOGY	\$6.34	34%	-58%	\$206	\$149	\$57	\$0	310	\$0.2	-\$41.6	3.6	0.4
IMCLONE SYSTEMS	\$13.33	44%	-41%	\$982	\$293	\$688	\$242	399	\$1.7	-\$168.0	1.7	2.8
IMMUNOGEN	\$2.37	20%	-79%	\$103	\$127	-\$25	\$0	105	-\$0.2	-\$12.9	9.9	0.3
IMMUNOMEDICS	\$2.80	13%	-83%	\$140	\$38	\$101	\$0	94	\$1.1	-\$11.5	3.3	0.9
MAXIM PHARMACEUTICALS	\$3.30	48%	-41%	\$ 77	\$108	-\$31	\$2	132	-\$0.2	-\$44.4	2.4	0.2
MEDAREX	\$2.79	15%	-82%	\$213	\$370	-\$157	\$175	297	-\$0.5	-\$216.5	1.7	0.3
NAPRO BIOTHERAPEUTICS	\$0.45	4%	-96%	\$13	\$12	\$2	\$25	189	\$0.0	-\$15.8	0.7	0.1
NEOPHARM	\$10.76	43%	-37%	\$176	\$102	\$74	\$0	72	\$1.0	-\$41.1	2.5	1.0
NEORX CORP	\$0.49	12%	-88%	\$ 13	\$12	\$1	\$5	118	\$0.0	-\$46.0	0.3	0.1
OSI PHARMACEUTICALS	\$14.78	34%	-61%	\$539	\$465	\$74	\$160	429	\$0.2	-\$88.6	5.2	0.8
OXIGENE	\$1.61	50%	-25%	\$ 20	\$14	\$6	\$0	15	\$0.4	-\$6.7	2.1	0.2
PRAECIS PHARMACEUTICALS	\$4.05	69%	-10%	\$210	\$209	\$1	\$33	na	na	-\$22.3	9.4	0.6
PROGENICS PHARMACEUTICALS	\$5.40	32%	-59%	\$ 68	\$42	\$27	\$0	80	\$0.3	-\$25.6	1.6	0.7
QLT PHOTOTHERAPEUTICS	\$9.09	43%	-49%	\$621	\$257	\$363	\$0	285	\$1.3	-\$48.3	5.3	1.3

SCICLONE PHARMACEUTICALS	\$4.75	95%	107%	\$175	\$25	\$151	\$6	na	na	-\$6.7	3.7	1.1
SEATTLE GENETICS	\$2.87	43%	-40%	\$ 88	\$31	\$57	\$0	na	na	-\$20.4	1.5	0.8
XENOVA GROUP PLC	\$3.25	33%	-66%	\$ 45	\$18	\$27	\$0	134	\$0.2	-\$8.8	2.1	2.5
Cancer Average	.	35%	-53%	\$194	\$94	\$100	\$19	.	\$0.6	-\$40.1	4.4	0.7
Cancer Median	.	32%	-61%	\$ 77	\$47	\$21	\$0	.	\$0.2	-\$22.3	1.7	0.5
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
ATHEROGENICS	\$8.60	96%	31%	\$313	\$41	\$272	\$0	79	\$3.4	-\$27.7	1.5	2.6
CORVAS INTERNATIONAL	\$1.74	26%	-70%	\$ 48	\$71	-\$23	\$12	95	-\$0.2	-\$26.2	2.7	0.2
CV THERAPEUTICS	\$17.64	39%	-54%	\$478	\$420	\$58	\$196	222	\$0.3	-\$99.3	4.2	0.9
QUESTCOR PHARMACEUTICALS	\$1.08	52%	-29%	\$ 42	\$ 9	\$32	\$3	38	\$0.9	-\$4.0	2.3	0.5
SCIOS	\$43.64	99%	118%	\$2,048	\$66	\$1,982	\$161	425	\$4.7	-\$87.3	0.8	3.6
TEXAS BIOTECHNOLOGY CORP	\$0.80	12%	-86%	\$35	\$47	-\$12	\$0	na	na	-\$23.4	2.0	0.2
Cardiovascular Average	.	54%	-15%	\$494	\$109	\$385	\$62	.	\$1.8	-\$44.6	2.3	1.3
Cardiovascular Median	.	52%	-29%	\$ 48	\$47	\$32	\$3	.	\$0.9	-\$26.2	2.0	0.9
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
3-DIMENSIONAL PHARMACEUTICALS	\$5.71	75%	-23%	\$129	\$75	\$54	\$5	204	\$0.3	-\$30.8	2.4	0.8
ARGONAUT TECHNOLOGIES	\$0.97	31%	-61%	\$19	\$29	-\$9	\$0	154	-\$0.1	-\$21.4	1.3	0.2
ARIAD PHARMACEUTICALS	\$1.79	29%	-53%	\$ 62	\$28	\$34	\$6	69	\$0.5	-\$31.3	0.9	0.4
ARQULE	\$2.37	18%	-81%	\$ 51	\$83	-\$32	\$8	385	-\$0.1	-\$21.9	3.8	0.2
ARRAY BIOPHARMA	\$4.08	31%	-60%	\$114	\$52	\$62	\$0	na	na	-\$4.9	10.7	0.9
BIOCRYST PHARMACEUTICALS	\$1.01	21%	-76%	\$ 18	\$27	-\$9	\$0	77	-\$0.1	-\$13.7	2.0	0.1
KOSAN BIOSCIENCES	\$5.50	59%	-23%	\$140	\$63	\$76	\$0	68	\$1.1	-\$29.5	2.1	1.0
PHARMACOPEIA	\$6.60	43%	-47%	\$155	\$142	\$13	\$0	800	\$0.0	-\$25.3	5.6	0.5
SYMIX TECHNOLOGIES	\$13.26	53%	-21%	\$409	\$119	\$290	\$0	204	\$1.4	na	na	2.7
VERTEX PHARMACEUTICALS	\$11.05	34%	-49%	\$841	\$651	\$190	\$315	1000	\$0.2	-\$133.8	4.9	1.1
Chemistry Average	.	39%	-49%	\$194	\$127	\$67	\$33	.	\$0.4	-\$34.7	3.8	0.8
Chemistry Median	.	34%	-49%	\$114	\$63	\$34	\$0	.	\$0.2	-\$23.6	2.3	0.8
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
CEPHALON	\$48.15	70%	-17%	\$2,657	\$637	\$2,020	\$871	1127	\$1.8	na	na	2.7
DOV PHARMACEUTICALS	\$5.64	47%	na	\$ 81	\$64	\$17	\$14	NA	NA	-\$10.4	6.2	1.0
GUILFORD PHARMACEUTICALS	\$3.43	33%	-60%	\$102	\$96	\$7	\$4	289	\$0.0	-\$58.3	1.6	0.3
INDEVUS PHARMACEUTICALS	\$2.06	22%	-75%	\$97	\$40	\$56	\$0	19	\$3.0	-\$19.3	2.1	0.3
MACROCHEM CORP	\$0.61	18%	-80%	\$ 17	\$10	\$7	\$0	32	\$0.2	-\$6.1	1.7	0.2
NEUROCRINE BIOSCIENCES	\$42.13	84%	19%	\$1,289	\$275	\$1,014	\$0	222	\$4.6	-\$80.9	3.4	3.1

ORASURE	\$6.82	79%	31%	\$256	\$13	\$243	\$3	221	\$1.1	-\$1.5	8.6	1.7
OSTEX INTERNATIONAL	\$1.94	72%	-10%	\$ 24	\$1	\$23	\$1	46	\$0.5	-\$4.5	0.2	0.5
QUIDEL CORP	\$3.15	44%	-50%	\$ 91	\$ 5	\$86	\$0	336	\$0.3	-\$4.8	1.0	0.6
SONUS PHARMACEUTICALS	\$2.20	31%	-60%	\$ 30	\$19	\$11	\$0	34	\$0.3	-\$13.1	1.5	0.5
TRINITY BIOTECH PLC	\$1.95	99%	26%	\$ 79	\$ 1	\$78	\$0	332	\$0.2	na	na	3.6
Diagnostic/imag. Average	.	57%	-25%	\$242	\$24	\$218	\$3	.	\$0.9	-\$13.2	2.1	2.5
Diagnostic/imag. Median	.	58%	-22%	\$ 91	\$18	\$78	\$0	.	\$0.5	-\$10.0	1.6	1.1
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
AASTROM BIOSCIENCES	\$0.30	34%	-66%	\$15	\$8	\$8	\$0	44	\$0.2	-\$9.8	0.8	0.1
AVIGEN	\$2.90	25%	-65%	\$ 58	\$125	-\$67	\$0	143	-\$0.5	-\$28.4	4.4	0.2
CELL GENESYS	\$7.94	44%	-47%	\$286	\$226	\$60	\$0	262	\$0.2	-\$50.8	4.4	1.0
DIACRIN	\$1.03	46%	-51%	\$ 18	\$40	-\$22	\$0	30	-\$0.7	-\$6.1	6.5	0.2
INTROGEN	\$2.19	41%	-52%	\$47	\$31	\$16	\$7	77	\$0.2	-\$22.8	1.4	0.5
RIBOZYME PHARMACEUTICALS	\$0.34	9%	-88%	\$ 7	\$15	-\$8	\$5	130	-\$0.1	-\$27.3	0.6	0.0
TARGETED GENETICS CORP	\$0.29	13%	-86%	\$ 15	\$17	-\$3	\$23	173	\$0.0	-\$19.3	0.9	0.1
TRANSGENE SA	\$1.52	53%	-35%	\$ 46	na	na	\$0	318	na	na	na	na
TRANSKARYOTIC THERAPIES	\$5.01	11%	-87%	\$175	\$288	-\$114	\$0	376	-\$0.3	-\$83.6	3.5	0.3
VALENTIS	\$4.95	5%	-88%	\$ 6	\$12	-\$6	\$0	58	-\$0.1	-\$18.6	0.6	0.0
VICAL	\$2.53	25%	-70%	\$ 51	\$120	-\$69	\$0	152	-\$0.5	-\$40.9	2.9	0.2
Gene therapy Average	.	28%	-67%	\$ 66	\$88	-\$20	\$3	.	-\$0.2	-\$30.8	2.6	0.3
Gene therapy Median	.	29%	-66%	\$ 32	\$31	-\$6	\$0	.	-\$0.1	-\$22.8	1.4	0.2
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
AVANT IMMUNOTHERAPEUTICS	\$1.09	44%	-19%	\$ 66	\$26	\$40	\$0	71	\$0.6	-\$1.1	23.8	0.3
ESSENTIAL	\$0.12	3%	-96%	\$ 2	\$41	-\$38	\$1	139	-\$0.3	-\$20.3	2.0	0.0
GENELABS TECHNOLOGIES	\$1.33	37%	-28%	\$ 71	\$12	\$59	\$0	90	\$0.7	-\$17.2	0.7	0.4
IMMUNE RESPONSE CORP	\$1.42	30%	-62%	\$ 14	\$1	\$13	\$3	129	\$0.1	-\$22.0	0.1	0.1
INTERMUNE	\$19.96	52%	-45%	\$631	\$343	\$288	\$150	57	\$5.1	-\$39.0	8.8	1.3
INTRABIOTICS	\$0.16	3%	-95%	\$ 6	\$35	-\$29	\$4	31	-\$0.9	-\$45.1	0.8	0.0
MEDIMMUNE	\$30.01	67%	-27%	\$7,540	\$454	\$7,086	\$218	877	\$8.1	-\$145.2	3.1	2.9
NABI BIOPHARMACEUTICALS	\$5.13	67%	-7%	\$199	\$44	\$155	\$0	615	\$0.3	na	na	1.2
NEOSE TECHNOLOGIES	\$6.24	19%	-80%	\$89	\$43	\$46	\$4	111	\$0.4	-\$23.8	1.8	0.5
SIGA TECHNOLOGIES	\$1.26	46%	-52%	\$14	\$ 1	\$13	\$0	12	\$1.1	-\$2.5	0.4	0.5
TRIMERIS	\$40.02	70%	5%	\$854	\$61	\$793	\$0	109	\$7.3	-\$72.6	0.8	3.0
VAXGEN	\$3.76	16%	-66%	\$ 54	\$26	\$28	\$0	80	\$0.4	-\$31.0	0.8	0.4
VERSOR	\$10.30	51%	-43%	\$272	\$73	\$199	\$1	63	\$3.2	-\$52.1	1.4	1.3
VION PHARMACEUTICALS	\$0.36	8%	-91%	\$ 10	\$13	-\$3	\$0	50	-\$0.1	-\$9.9	1.3	0.1
VIROLOGIC	\$0.92	27%	-61%	\$ 23	\$ 6	\$17	\$0	204	\$0.1	-\$22.3	0.3	0.2
VIROPHARMA	\$1.73	10%	-89%	\$45	\$176	-\$131	\$156	418	\$0.4	na	na	0.2
XOMA LTD	\$3.61	40%	-55%	\$254	\$36	\$218	\$58	193	\$1.1	-\$49.0	0.7	-18.5

Infection Average	.	35%	-54%	\$597	\$82	\$515	\$35	.	\$1.6	-\$36.9	3.1	-0.4
Infection Median	.	39%	-54%	\$ 60	\$36	\$34	\$1	.	\$0.5	-\$23.1	0.9	0.4
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
AMYLIN PHARMACEUTICALS	\$15.34	81%	73%	\$1,256	\$180	\$1,076	\$0	150	\$7.2	-\$125.2	1.4	2.4
BIO-TECHNOLOGY GENERAL CORP	\$2.55	41%	-52%	\$150	\$20	\$130	\$14	378	\$0.3	na	na	0.7
INSMED INC	\$0.49	15%	-82%	\$ 16	\$ 0	\$16	\$0	na	na	-\$2.2	0.0	9.6
NPS PHARMACEUTICALS	\$17.36	48%	-42%	\$529	\$158	\$371	\$0	146	\$2.5	-\$73.1	2.2	1.4
ZONAGEN	\$0.93	19%	-80%	\$ 11	\$27	-\$17	\$0	10	-\$1.7	na	na	0.1
Metabolic Average	.	41%	-37%	\$392	\$77	\$315	\$3	.	\$2.1	-\$66.8	1.2	2.8
Metabolic Median	.	44%	-47%	\$ 83	\$24	\$73	\$0	.	\$1.0	-\$37.7	1.2	1.2
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
ALBANY MOLECULAR RESEARCH	\$14.50	48%	-48%	\$470	\$121	\$349	\$5	532	\$0.7	na	na	2.6
BIOPURE CORP	\$3.11	23%	-55%	\$ 96	\$30	\$66	\$10	211	\$0.3	-\$50.4	0.6	0.2
BIORELIANCE CORP	\$17.00	61%	-18%	\$144	\$36	\$108	\$11	556	\$0.2	na	na	2.6
BIOTIME	\$1.59	41%	-59%	\$ 21	\$ 2	\$20	\$2	12	\$1.6	-\$2.3	0.8	0.7
CARRINGTON LABORATORIES	\$1.03	40%	-49%	\$10	\$ 2	\$8	\$0	181	\$0.0	-\$2.2	1.1	0.2
COLLAGENEX PHARMACEUTICALS	\$9.06	75%	-9%	\$103	\$ 5	\$98	\$0	155	\$0.6	na	na	1.2
COLUMBIA LABORATORIES	\$3.15	53%	-17%	\$112	\$ 4	\$107	\$10	19	\$5.7	-\$7.5	0.6	0.9
CYANOTECH CORP	\$0.51	43%	-54%	\$ 9	\$ 0	\$9	\$3	53	\$0.2	-\$2.2	0.1	0.4
CYTRX CORP	\$0.41	39%	-38%	\$ 9	\$ 2	\$7	\$0	5	\$1.3	-\$9.9	0.2	0.1
DISCOVERY LABORATORIES	\$1.85	56%	-40%	\$ 61	\$11	\$50	\$0	50	\$1.0	-\$18.1	0.6	0.8
GTC BIOTHERAPEUTICS	\$1.36	35%	-61%	\$38	\$66	-\$28	\$13	168	-\$0.2	-\$27.9	2.4	0.2
ICON PLC	\$25.99	75%	-16%	\$307	\$0	\$307	\$0	1262	\$0.2	na	na	na
IMMUCOR	\$19.73	76%	187%	\$249	\$ 6	\$243	\$23	481	\$0.5	na	na	8.6
INSITE VISION	\$0.80	36%	-58%	\$ 20	\$ 4	\$17	\$0	39	\$0.4	-\$12.4	0.3	0.2
INVITROGEN CORP	\$31.04	79%	-32%	\$1,601	\$712	\$889	\$512	2726	\$0.3	na	na	0.9
MOLECULAR DEVICES CORP	\$13.16	62%	-38%	\$202	\$51	\$150	\$0	370	\$0.4	na	na	1.1
NORTHFIELD LABORATORIES	\$5.82	65%	-23%	\$ 83	\$12	\$71	\$0	60	\$1.2	-\$12.6	1.0	0.7
OSTEOTECH	\$7.50	66%	-10%	\$127	\$19	\$108	\$17	365	\$0.3	na	na	2.0
PAIN THERAPEUTICS	\$1.85	15%	-81%	\$ 50	\$54	-\$4	\$0	26	-\$0.1	-\$12.2	4.4	0.5
PHARMACEUTICAL PRODUCT DEVELOP	\$31.37	89%	1%	\$1,743	\$147	\$1,596	\$7	4375	\$0.4	na	na	6.5
PHARMACYCLICS	\$3.30	36%	-54%	\$ 53	\$109	-\$56	\$0	176	-\$0.3	-\$26.9	4.1	0.2
PHARMOS CORP	\$0.98	49%	-46%	\$ 55	\$25	\$30	\$0	70	\$0.4	-\$21.8	1.2	0.5
QIAGEN NV	\$5.84	34%	-62%	\$849	\$30	\$819	\$0	na	na	na	na	17.1
QUINTILES TRANSNATIONAL CORP	\$12.40	64%	-25%	\$1,461	\$ 1	\$1,461	\$0	17224	\$0.1	na	na	na
SANGSTAT MEDICAL CORP	\$8.37	30%	-60%	\$221	\$107	\$114	\$15	263	\$0.4	na	na	0.7
SICOR	\$14.84	78%	-7%	\$1,737	\$201	\$1,536	\$25	1851	\$0.8	na	na	2.2

SUPERGEN	\$3.38	39%	-61%	\$111	\$27	\$84	\$0	115	\$0.7	-\$80.4	0.3	0.4
TRIPOS	\$5.30	20%	-76%	\$ 47	\$10	\$36	\$3	267	\$0.1	-\$3.1	3.3	1.3
Other Average	.	51%	-32%	\$357	\$64	\$293	\$23	.	\$0.6	-\$19.3	1.4	2.0
Other Median	.	49%	-40%	\$103	\$19	\$84	\$1	.	\$0.4	-\$12.3	0.9	0.8
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
AMGEN	\$54.64	87%	-6%	\$70,325	\$4,042	\$66,283	\$3,040	7700	\$8.6	na	na	3.7
BIOGEN	\$35.54	62%	-33%	\$5,298	\$828	\$4,469	\$39	1992	\$2.2	na	na	6.4
CHIRON CORP	\$36.52	74%	-16%	\$6,870	\$945	\$5,925	\$415	3736	\$1.6	na	na	2.8
GENENTECH	\$35.36	65%	-25%	\$18,125	\$1,124	\$17,001	\$0	4950	\$3.4	na	na	2.7
GENZYME CORP	\$31.18	60%	-30%	\$6,690	\$441	\$6,249	\$869	5200	\$1.2	na	na	2.4
GILEAD SCIENCES	\$34.00	85%	-3%	\$6,687	\$625	\$6,062	\$250	1000	\$6.1	na	na	7.1
IDEC PHARMACEUTICALS CORP	\$28.75	40%	-54%	\$4,400	\$947	\$3,452	\$861	692	\$5.0	na	na	4.9
Revenue-driven Average	.	67%	-24%	\$16,914	\$1,279	\$15,635	\$782	.	\$4.0	na	na	4.3
Revenue-driven Median	.	69%	-20%	\$6,689	\$887	\$5,994	\$333	.	\$2.8	na	na	3.2
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
CUBIST PHARMACEUTICALS	\$8.22	36%	-42%	\$235	\$147	\$88	\$209	180	\$0.5	-\$68.0	2.2	0.9
DISCOVERY PARTNERS	\$2.59	32%	-57%	\$ 63	\$70	-\$7	\$0	225	\$0.0	-\$3.2	21.6	0.3
DIVERSA	\$7.01	51%	-35%	\$251	\$164	\$87	\$11	276	\$0.3	-\$26.8	6.1	0.9
DYAX	\$1.72	33%	-65%	\$ 34	\$34	\$0	\$16	239	\$0.0	-\$22.7	1.5	0.2
ISIS PHARMACEUTICALS	\$4.48	25%	-69%	\$247	\$292	-\$45	\$179	434	-\$0.1	-\$70.3	4.2	0.4
LIGAND PHARMACEUTICALS	\$4.73	23%	-67%	\$338	\$35	\$303	\$4	351	\$0.9	-\$28.2	1.3	0.5
NEUROGEN CORP	\$3.78	26%	-72%	\$ 68	\$84	-\$16	\$20	200	-\$0.1	-\$31.2	2.7	0.4
ONYX PHARMACEUTICALS	\$7.20	80%	87%	\$155	\$50	\$105	\$5	85	\$1.2	-\$43.3	1.2	0.8
REGENERON PHARMACEUTICALS	\$18.34	68%	-19%	\$808	\$300	\$508	\$200	575	\$0.9	-\$131.3	2.3	1.4
REPLIGEN CORP	\$3.47	77%	20%	\$ 95	\$17	\$77	\$0	40	\$1.9	-\$4.3	4.0	0.6
TULARIK	\$4.01	18%	-78%	\$220	\$175	\$45	\$9	380	\$0.1	-\$91.8	1.9	0.6
Screening Average	.	43%	-36%	\$228	\$124	\$104	\$59	.	\$0.5	-\$47.4	4.4	0.6
Screening Median	.	35%	-49%	\$188	\$77	\$61	\$10	.	\$0.4	-\$29.7	2.2	0.6
COMPANY	02/28/03 Close	% 52wk High	% change from 02/28/02	Market Cap (\$M)	Cash & Mkt. Sec. (\$M)	Tech Value (\$M)	LT Debt plus Convert	# of Staff	Tech Value / Staff (\$M)	Est. Burn Rate (\$M)	Survival Index (Yrs)	Equity Multiple
CELLEGY PHARMACEUTICALS	\$4.16	59%	-28%	\$ 81	\$ 5	\$76	\$1	36	\$2.1	-\$6.5	0.8	0.9
LIFECCELL CORP	\$2.38	63%	-16%	\$ 50	\$ 5	\$44	\$1	138	\$0.3	na	na	0.6
LIFECORE BIOMEDICAL	\$7.25	62%	-19%	\$ 93	\$ 1	\$93	\$6	200	\$0.5	-\$4.2	0.2	2.0
Wound Average	.	61%	-21%	\$ 75	\$ 4	\$71	\$2	.	\$1.0	-\$5.3	0.5	1.2
Wound Median	.	62%	-18%	\$ 65	\$ 3	\$60	\$1	.	\$0.7	-\$4.2	0.8	0.9
Grand Average	.	42%	-44%	\$782	\$143	\$645	\$57	.	\$0.8	-\$39.0	2.8	1.1
Grand Median	.	39%	-52%	\$101	\$47	\$45	\$0	.	\$0.4	-\$27.5	1.7	0.6

Footnotes to the table:

- Technology value: Market cap - cash (and cash equivalents)
- LT debt plus convert.: Long-term debt plus convertible debt
- Estimated burn rate: Net loss from the last available quarterly report, X4. Companies with net profit (instead of loss) are indicated as "na."
- Survival index: Cash (plus cash equivalents) / Estimated burn rate.
- Equity multiple: Market cap / (common stock + preferred stock + additional paid-in capital).
- Median: Middle value in a set of values
- The information contained in the February 2003 Stock Report has been obtained from public sources. Where information is not available, it is indicated as "na." Recombinant Capital cannot warrant the ultimate accuracy of the data. All data are subject to change.
- Most of the accounting figures are from quarterly reports as of 9/02, with some figures adjusted for one-time write-offs.

Highlights From The February 2003 Stock Report:

We published the first Financial Snapshot in February 2000. Now, three years later, we thought it might be instructive to profile the changes that have occurred in the public biotech sector during that time.

	February 28, 2003	February 28, 2002	February 28, 2001	February 25, 2000
Number of companies	226	252	270	250
Percent trading at less than 50% of 52-week high	65%	46%	79%	4%
Negative one-year return	89%	73%	75%	9%
Positive one-year return	10%	26%	10%	85%
Market cap less than \$200M	65%	54%	46%	36%
Market cap greater than \$2B	5%	6%	10%	14%
Average/median market cap (M)	\$782 / \$101	\$968 / \$179	\$1,194 / \$237	\$1,674 / ND
Technology value per staff (range, M)	-\$1.7 -- \$8.6	-\$24.7 -- \$37.1	-\$24.8 -- \$36.3	\$2 -- \$73.6
Average/median cash (M)	\$143 / \$47	\$140 / \$55	\$116 / \$48	\$59 / ND
Survival index less than 1 year	27%	19%	18%	28%
Average/median survival index (Years)	2.8 / 1.7	5.7 / 2.4	9.3 / 2.9	2.7 / ND

Thanks to the genomics bubble, 2000 was a great year for the biotech sector.

- The Nasdaq Biotech Index gained 23%, while the Nasdaq Composite Index lost 39%.
- Stock prices soared into the stratosphere, with the Biotech Index hitting its all time

high on March 6. At the end of February 2000, 85% of the stocks in our universe posted positive one-year returns, with 6% of them exhibiting gains of at least 1,000%.

- About 14% of the companies in our universe had market caps exceeding \$2 billion. The average market cap was nearly \$1.7 billion. (We did not calculate the median value.)

Since then, as we know, it's been downhill all the way.

- In 2001, the Nasdaq Biotech Index shed 16% (still outperforming the Comp, which dropped by 21% over the 12-month period). In 2002, the Biotech Index lost 54%, underperforming the Comp, which shed 46% over the 12-month period.

- In 2001, only 10% of the companies in our universe posted a positive one-year return. That number jumped to 26% in 2002, but now it's back down to 10%.

- In 2001, 10% of the companies we track had market caps exceeding \$2 billion. Since then, that number has declined even further: By February 2003, a mere 5% had market caps of at least \$2 billion. And, if you omit the 7 revenue-driven firms from the calculation, that number drops to less than 2% -- only 4 companies out of the 226 in our universe.

- The average market cap declined from about \$1.2 billion in 2001 to \$782 million in 2003 -- a 35% drop. The median market cap fared worse, falling by more than 50% -- from \$237 million in 2001 to \$101 million in 2003.

- Interestingly, when we survey the entire group, we find that the amount of cash on hand hasn't changed that much. In 2001, the median cash was \$48 million; it's \$47 million in 2003. And the average has actually increased somewhat: In 2001, it was \$116 million; in 2003, it's \$143 million.

- The increase in the average value is due to those firms that raised considerable amounts of cash during the genomics boom in 2000, as well as those lucky few that have continued to garner funds over the last several years. Sixty-nine of the companies on our list (about 31%) have cash reserves of at least \$100 million and 12 of those have at least \$500 million in the bank.

- Yet, we know that many firms are running out of money -- especially since the well has been dry for so long. In reality, 20% (46/226) of the companies we track are currently sitting on cash reserves of \$10 million or less. Many, if not most of those, initiated cost-savings efforts in 2002 to stretch what little money they have until financing becomes available once again. Long may they last.

Satomi Degami, Research Manager, Recombinant Capital
Jennifer Van Brunt, Editor, *Signals*

originally published 03/06/2003

Copyright © 2003. **Signals** is an online magazine of analysis for biotechnology executives. To contact the **Signals** editorial department, send e-mail to signals_edit@recap.com. **Signals** is published by: Recombinant Capital, 2033 N Main Street, Suite 1050, Walnut Creek, California 94596-3722
Phone: 925 952 3870

